Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday.
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday and Moderna stock skidded in early action.
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results